Gavi, the Vaccine Alliance

GAVI, known as Gavi, the Vaccine Alliance, is a global health partnership that combines efforts from both public and private sectors. Its main aim is to improve access to vaccines in low-income countries. In 2016, Gavi was responsible for over half of the total funding provided by donors for health initiatives, and it played a significant role in funding immunization efforts.

English, French

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#184044

United States

#139140

Health/Public Health and Safety

#109

Traffic sources

Monthly visitors

Articles

Les pays du bassin du lac Tchad s’unissent pour endiguer la polio

1 week ago | gavi.org | Nalova Akua

Ndjidda Sali et Fadimatou Hamadou, respectivement boucher et restauratrice dans la région de l’Extrême-Nord du Cameroun, ont été confrontés à un dilemme délicat le 24 avril 2025 : fermer boutique pour faire vacciner leurs enfants contre la polio, ou maintenir leurs activités commerciales au risque de rater cette opportunité cruciale. Tous deux ont choisi sans hésiter de privilégier la santé de leurs enfants.
Modelling rabies: how smarter supply chains could save lives

1 week ago | gavi.org | Linda Geddes

Every year, tens of thousands of people die from rabies – a preventable disease – because they couldn’t get the vaccine in time. Often, the root cause is a dog bite and a health system unprepared for the unpredictable. Now researchers are using real-world data and simulations to try and map a more resilient future. Rabies is caused by a virus that attacks the brain and is almost universally fatal once symptoms appear.
In one of Nairobi’s most diverse pockets, polyglot health workers and chiefs in uniform boost vaccine uptake

2 weeks ago | gavi.org | Lenah Bosibori

It’s early on a Friday morning in Eastleigh North, on the outskirts of Nairobi, Kenya’s capital. Already, a hot sun is beaming down on this diverse and vibrant neighbourhood – the area is home to a mix of Kenyans, refugees and other immigrants from across Africa. Josiah Kiweu, Eastleigh North Location Chief – a local-level administrative official under Ministry of the Interior – is assembling his team for the day’s work. Today, they will visit households to monitor uptake of different vaccines.
West Nile virus reaches the UK: should you be worried?

2 weeks ago | gavi.org | Linda Geddes

Genetic traces of West Nile virus have been detected in UK mosquitoes for the first time – one of the northernmost confirmed detections of the virus in Europe to date. The discovery marks a small, but significant development in the ongoing march of vector-borne diseases to higher latitudes, as climate and ecological conditions shift. West Nile virus belongs to the same family as yellow fever and dengue, and is similarly spread via mosquito bites.
Atomic precision: Pioneering HIV vaccine triggers key immune response

3 weeks ago | gavi.org | Linda Geddes

In a step toward ending one of the world’s deadliest pandemics, researchers have shown that it’s possible to spark the beginnings of a broadly neutralising antibody response against HIV – one of vaccinology’s greatest challenges. HIV continues to infect more than a million people each year, most of them in sub-Saharan Africa. More than 600,000 people died from HIV-related causes in 2023. Across the participants we saw an immune response that indicates that we're on the right track.
How new vaccines could revolutionise our relationship with tuberculosis

3 weeks ago | gavi.org | Linda Geddes

Tuberculosis (TB) has scourged humanity for millennia and remains the deadliest infectious disease worldwide. Although a cheap and partially effective vaccine has long been available, new ones are urgently needed. News that a potential breakthrough vaccine – one that many hope could be the first new TB vaccine for a century – has reached its clinical trial recruitment target ahead of time is understandably stirring optimism. It’s not alone, either: several other contenders are close on its heels.
Study suggest dual COVID-19/flu shot is more effective than individual vaccines

3 weeks ago | gavi.org | Linda Geddes

A combined mRNA vaccine against COVID-19 and seasonal influenza appears to trigger stronger immune responses against both viruses compared to existing vaccines, late-stage clinical trial data suggests. Although COVID-19 might have faded from news headlines, there are still an estimated 2.3 billion cases a year, and roughly 1 billion influenza cases annually as well. Despite vaccines being available to protect us against both diseases, not enough people are taking them.
Your fridge might be a breeding ground for bacteria - here’s how to fix it

4 weeks ago | gavi.org | Judith Evans

The kitchen is often the heart of the home – a place where families gather and meals begin. And at the start of it all? The fridge. This is where we safely store much of our food, and as technology advances, fridges are getting smarter: being able to track inventory, suggest recipes, even displaying the news. But of all their features, temperature remains the most critical.
Universal snake antivenom a step closer thanks to man bitten hundreds of times

1 month ago | gavi.org | Linda Geddes

Antibodies from a man who has deliberately courted snakebites and injected himself with venom for nearly two decades have been used to create the most broadly protective antiserum yet. The three-agent cocktail protected mice against poisoning with venom from 19 of the world’s deadliest snakes, including various cobras, kraits, the Russell’s viper and western diamondback rattlesnake.
Left arm, or right? The simple choice that might influence your response to vaccines

1 month ago | gavi.org | Linda Geddes

Receiving a booster vaccine in the same arm as your first shot could help to generate a more effective immune response more quickly, data suggests. If confirmed in larger groups of individuals and for other vaccines, the discovery could eventually help to improve immunisation strategies. The same-arm strategy could help achieve herd immunity faster – particularly important for rapidly mutating viruses where speed of response matters.